Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Sally Church

Sally Church

Interested in Pharma, Biotech, Science and cancer... Find me at http://www.pharmastrategyblog.com also love food, wine, the NFL and cricket. Hi!
ASH 2011 Update 1: Bruton’s Kinase Inhibitors (BTK) - http://pharmastrategyblog.com/2011...
What’s hot at SABCS – Update 2 – advanced breast cancer - http://pharmastrategyblog.com/2011...
Follow the American Society of Hematology ASH conversations! - http://pharmastrategyblog.com/2011...
What’s hot at the American Society of Hematology 2011? - http://pharmastrategyblog.com/2011...
Video preview of San Antonio Breast Cancer Symposium 2011 - http://pharmastrategyblog.com/2011...
Follow the conversation from 2011 San Antonio Breast Cancer Symposium - http://pharmastrategyblog.com/2011...
EGFR activates mTORC2 in glioblastoma – a potential role for new therapies - http://pharmastrategyblog.com/2011...
Exciting new approach to targeted therapy in prostate cancer - http://pharmastrategyblog.com/2011...
Update from AACR Molecular Targets 2011 #2 – Angiogenesis - http://pharmastrategyblog.com/2011...
Update from AACR Molecular Targets 2011 #1 – Breast Cancer - http://pharmastrategyblog.com/2011...
Epigenetics – an emerging new potential treatment for lung cancer? - http://pharmastrategyblog.com/2011...
Update on pancreatic Neuroendocrine Tumours (NET) - http://pharmastrategyblog.com/2011...
Redefining subsets of triple negative breast cancer - http://pharmastrategyblog.com/2011...
How a metabolic protein PKM2 may have a key role in tumorigenesis - http://pharmastrategyblog.com/2011...
Excellent news in Advanced Prostate Cancer – Medivation’s MDV3100 meets primary endpoint - http://pharmastrategyblog.com/2011...
Understanding cancer metastasis – possible new therapeutic targets - http://pharmastrategyblog.com/2011...
A year in the life of Pharma Strategy Blog - http://pharmastrategyblog.com/2011...
Update on EGFR resistance in lung cancer: new directions - http://pharmastrategyblog.com/2011...
Update on cabozantinib in medullary thyroid cancer - http://pharmastrategyblog.com/2011...
Useful resource on new therapies for lung cancer - http://pharmastrategyblog.com/2011...
The elusive mystery of KRAS and EGFR inhibitors in colorectal cancer - http://pharmastrategyblog.com/2011...
Update on ADCs and immunotoxins in hematologic malignancies - http://pharmastrategyblog.com/2011...
Ovarian cancer patients with BRCA2 mutated tumors live longer - http://pharmastrategyblog.com/2011...
Other ways to read this feed:Feed readerFacebook